Recent

% | $
Quotes you view appear here for quick access.

Optimer Pharmaceuticals, AŞ Message Board

  • loriskhireward loriskhireward Nov 16, 2011 10:04 AM Flag

    Gotta like this comment from Zack's...

    just a tidbit from today's comments:

    However, we are concerned about Vancocin (approved for the treatment of clostridium difficile infection), which faces competition from Optimer Pharmaceuticals Inc.’s (NasdaqGM:OPTR - News) Dificid (fidaxomicin), which is marketed in the US. The candidate is currently under review in the EU. We believe that Dificid could turn out to be a major threat to Vancocin, which is currently not protected by any patent.

    I guess "doc" knows more...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Lo! wasssup bu!

      what would have been more concerning is dificid with da same price as vanco... pedro may just have gone a little gone overboard with da pricing... but das good, it's all good!...
      these drugs are a lot cheaper than sayyy... provenge whose benefit is to extend 4 months of life... these two drugs actually saves life... provenge costs $93,000 to a mere $2,800 for dificid and $1,500 for vanco!... yikes! wasssup wid dat?

      on second thought pedro should have gone gusto with pricing!!!...

      aloha bu!

      • 1 Reply to funindasun_1
      • lol...I just don't like a "doc" telling me he's going to use a less effective drug just because it's been his "tried & true" treatment. when a new, more effective drug comes out, i expect the drug to gain acceptance, and not resistance 2nd to cost BEFORE considering the heavy expense burden placed on payers (govt type & pvt insur) and hospitals who are having to explain this dinosaur-like behavior. imo, of course - aloha, and keep the tip up!